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Abstract
The human hyaluronan receptor for endocytosis (hHARE) mediates the endocytic clearance of hyaluronan (HA) and chondroitin
sulfate from lymph fluid and blood. Two hHARE isoforms (190
and 315 kDa) are present in sinusoidal endothelial cells of liver,
spleen, and lymph nodes (Zhou, B., McGary, C. T., Weigel, J. A.,
Saxena, A., and Weigel, P. H. (2003) Glycobiology 13, 339–349).
Here we report the specificity and function of the 190-kDa HARE,
expressed without the larger isoform, in Flp-In 293 cell lines
(190hHARE cells). Like the native protein, recombinant hHARE
contains ~25 kDa of N-linked oligosaccharides, binds HA in a ligand blot assay, cross-reacts with three anti-rat HARE monoclonal antibodies, and is inactivated by reduction. The 190hHARE
cell lines mediated rapid, continuous 125I-HA endocytosis and
degradation for >1 day. About 30–50% of the total cellular receptors were on the cell surface, and their recycling time for reutilization was ~8.5 min. The average Kd for the binding of HA to the
190-kDa hHARE at 4 °C was 7 nm with 118,000 total HA binding
sites per cell. Competition studies at 37 °C indicated that the 190kDa hHARE binds HA and chondroitin better than dermatan sulfate and chondroitin sulfates A, C, D, and E, but it does not bind to
heparin, heparan sulfate, or keratan sulfate. Although competition
was observed at 37 °C, none of the glycosaminoglycans tested, except HA, competed for 125I-HA binding by 190hHARE cells at 4
°C. Anti-HARE monoclonal antibodies #30 and #154, which do
not inhibit 125I-HA uptake mediated by the 175-kDa rat HARE,
partially blocked HA endocytosis by the 190-kDa hHARE. We
conclude that the 190-kDa hHARE can function independently of
other hHARE isoforms to mediate the endocytosis of multiple glycosaminoglycans. Furthermore, the rat and human small HARE
isoforms have different glycosaminoglycan specificities and sensitivities to inhibition by cross-reacting antibodies.
Abbreviations: HA, hyaluronic acid, hyaluronate, or hyaluronan; CS,
chondroitin sulfate; CS-A, chondroitin 4-sulfate; CS-C, chondroitin
6-sulfate; CS-D, chondroitin 2,6-sulfate; CS-E, chondroitin 4,6-sulfate;
DS, dermatan sulfate; ECM, extracellular matrix; GAG, glycosaminoglycan; HARE, HA receptor for endocytosis; hHARE, human HARE;
HBSS, Hanks’ balanced salt solution; Hep, heparin; HS, heparan sulfate; KS, keratan sulfate; LECs, liver sinusoidal endothelial cells; mAb,
monoclonal antibody; PBS, phosphate-buffered saline; rHARE, rat
HARE; SK-HARE, stable SK-Hep-1 cell lines expressing recombinant
rat HARE; Tris, trishydroxymethylamino methane; TBS, Tris-buffered
saline; TBST, Tris-buffered saline containing 0.05% Tween 20; BSA,
bovine serum albumin; DMEM, Dulbecco’s modified Eagle’s medium;
Chon, chondroitin

Multiple extracellular binding proteins and cell surface receptors for HA facilitate many biological activities that are important during complex cellular processes, including development, wound healing, and invasion and metastasis of some
cancers (1–5). Due to the rapid turnover of HA in many tissues
(6), very high HA levels could occur locally, in lymph fluid, or
in plasma. Therefore, efficient mechanisms for HA uptake and
degradation are present in mammals to regulate the amount of
HA present in a variety of physiological conditions (reviewed
in References 2 and 7).
The endocytic clearance receptor for HA, which is designated HARE (HA receptor for endocytosis), is abundant in the
sinusoidal endothelial cells of liver, spleen, and lymph nodes
(8–10). The biological activity of this clearance receptor was
discovered in rodents in 1981 (11–13), and the protein was finally purified by Zhou et al. in 1999 (14). Earlier studies using
isolated rat LECs indicated that HARE mediates the binding
and endocytosis of HA via the coated-pit pathway and that
this receptor also recognizes and internalizes chondroitin sulfates (15–17). Unlike the rat HARE proteins, which have been
studied extensively in isolated rat LECs, there have been no
cellular studies of the human HARE proteins. Human LECs
are not available commercially, and to date, no cell lines have
been identified that express either the 190- or 315-kDa hHARE
isoforms. Consequently, very little is known about the GAG
specificity or function of human HARE.
In both rat (14) and human (10), two isoforms of HARE are
present with molecular masses of 175 or 300 kDa and 190 or
315 kDa, respectively. The human ~315-kDa HARE is a complex composed of two disulfide-bonded subunits of about
250 and 220 kDa, in a ratio of ~2:1 (10). In contrast, the small
hHARE isoform contains a single subunit. All subunits in
both hHARE isoforms, although they are different sizes, appear to be derived by proteolysis from the same precursor
protein (9), which is Stabilin 2 (18). Full-length Stabilin 2 is a
very large putative protein (2551 amino acids), whose synthesis and processing have not yet been fully elucidated. For example, it is not known if the largest subunit in the 315-kDa
hHARE corresponds to full-length Stabilin 2 or to a truncated
form of the protein. The small rat and human HARE proteins
are not encoded directly by mRNA. We recently demonstrated
(9) that the native small rHARE isoform contains the C-terminal 1431 residues of the predicted full-length protein and that
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this smaller HARE, when expressed in SK-Hep-1 cells in the
absence of the large isoform, colocalizes with clathrin as expected for a coated-pit-coupled endocytic HA receptor (19).
The two rat HARE species, therefore, appear to be functionally
independent isoreceptors for HA.
In the present study, we have created an artificial spleen
cDNA for the 190-kDa hHARE to assess its functionality and
GAG specificity in stable cell lines. In addition to demonstrating that this smaller hHARE isoform can function as an endocytic, recycling receptor in the absence of the larger hHARE,
we found that the human protein has slightly different specificity for various GAGs than the highly related rat 175-kDa
HARE isoform. Unexpectedly, several anti-HARE mAbs
showed very different reactivity with the rat and human recombinant HARE proteins and were able to block partially the
internalization of HA by cells expressing the 190-kDa hHARE.
Experimental Procedures
Materials and Buffers—Na125I was from Amersham Biosciences, and
was prepared as described previously (20) using HA oligosaccharides (MW = 133,000 based on gel permeation chromatography coupled to multiangle laser light scattering analysis), modified only at their
reducing ends to contain covalently attached hexylamine. Male SpragueDawley rats (200 g) were from Charles River Labs. BSA Fraction V and
fetal bovine serum were from Intergen Co. Collagenase was from Roche
Applied Science. The preparation and characterization of mouse mAbs
raised against the rat 175-kDa HARE were described previously (8). Tris,
SDS, ammonium persulfate, N,N′-methylenebisacrylamide, and SDSPAGE standards were from Bio-Rad. Digitonin, from ACROS Organics, was prepared as a 25% (w/v) stock solution in Me2SO and then diluted into medium as required. Unless noted otherwise, other chemicals
and reagents were from Sigma Chemical Co. All GAGs (with the exception of heparin, which came from Sigma) were obtained from Seikagaku
Corp. The weight-average molecular masses (determined by gel permeation chromatography coupled to multiangle laser light scattering analysis) for all but two of the GAGs were 14.2–38.8 kDa. The two exceptions
were Chon (7.4 kDa) and CS-E (187.7 kDa). Nitrocellulose membranes
were from Schleicher & Schuell. HBSS and PBS were prepared according
to the Invitrogen catalog formulations. Z-buffer contains 60 mm dibasic sodium phosphate and 40 mm monobasic sodium phosphate, pH 7.0,
10 mm KCl, 1.0 mm MgSO4, and 50 mm 2-mercaptoethanol. TBS contains 20 mm Tris-HCl, pH 7.0, and 150 mm NaCl. TBST is TBS containing
0.05% (v/v) Tween 20.
Construction of hHARE Expression Vector—The 190-kDa hHARE coding region was amplified from pooled lymph node cDNAs (Marathon system; Clontech) using Advantage 2 polymerase (Clontech), and gene-specific forward (5′-GGATCCTCCTTACCAAACCTGCTCATGCGG-3′) and
reverse (5′-GGATCCCAGTGTCCTCAAGGGGTCATTG-3′) primers. The
PCR product representing the artificial cDNA was then purified by agarose gel electrophoresis using a 0.8% gel containing 0.002% crystal violet
for visualization. The band was excised, gene-cleaned, ligated into pCRXL-TOPO, and transformed into TOP10 Escherichia coli cells (Invitrogen).
Clones were selected and screened for the full-length insert by restriction
digestion and PCR analysis, and a correct clone was used to prepare and
isolate the expression vector. The hHARE cDNA was then cut out of the
pCR-XL-TOPO plasmid and inserted into the BamHI site of pSecTag/
FRT/V5-His-TOPO (Invitrogen). This vector provides a κ light chain secretion signal fused at the N terminus of the hHARE reading frame and
two epitope tags (V5 and His-6) fused at the C terminus of the gene product. After transformation into TOP10 E. coli cells, several clones were selected and size and orientation of the cDNA insert were verified. The complete sequences of promoter, fusion, and cDNA regions of the final clones
were determined and confirmed to be correct.
Selection and Characterization of Stable Transfectants Expressing the 190kDa hHARE—Flp-In 293 cells (3 × 106; from Invitrogen) were plated in 100mm tissue culture dishes the day prior to transfection. Cells in 10 ml of
antibiotic-free medium were transfected by addition of 750 μl of serumfree DMEM containing 9 μg of pOG44 (which encodes the Flp-In recombinase), 1 μg of pSecTag-190hHARE, and 20 μl of LipofectAMINE 2000
(Invitrogen). Two days post-transfection the medium was replaced with
DMEM containing 100 μg/ml hygromycin B (Invitrogen). Due to the
build-up of dead cells, the medium was changed every 2–3 days. Visible colonies were observed at days 10–14 and then isolated using cloning
125I-HA
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rings or collected directly with a plastic pipette tip. Isolated colonies were
grown to confluence in 24-well dishes in 1.0 ml of DMEM with 100 μg/ml
hygromycin B. After a monolayer of cells had developed from each clone,
the cells were scraped and suspended in 1.0 ml of fresh medium. One portion (100 μl) of cells was re-seeded and allowed to grow for subsequent
procedures. Another 100 μl of cells was resuspended in DMEM plus 100
μg/ml Zeocin and allowed to grow for 1 week to test for Zeocin sensitivity. A third portion (400 μl) of cells was pelleted and resuspended in 4×
Laemmli sample buffer (21) to test for HARE protein expression by SDSPAGE and Western analysis. The Western blot was probed with anti-V5
antibody (Bethyl Laboratories; 1:5000 dilution) in TBST.
The remaining 400 μl of cell suspension was pelleted and assayed
for β-galactosidase activity. Both the Zeocin and β-galactosidase tests indicate whether pSecTag-190-kDa hHARE was inserted correctly and
uniquely into the Flp-In recombination site by the Flp-In recombinase encoded by pOG44. The recombinase is lost during subsequent cell divisions, because the encoding plasmid lacks an antibiotic selection gene. For
the β-galactosidase assay, a clonal cell pellet was resuspended in 250 μl
of 0.5% Triton X-100 in PBS, and 10 μl of cell lysate per well (in a 96-well
plate) was combined with 20 μl of distilled deionized H2O, 70 μl of Z-buffer, and 20 μl of 4 mg/ml o-nitrophenyl-β-d-galactoside in Z-buffer. After 15 min at 37 °C, the enzyme reaction was terminated by the addition of
0.1 ml 1 m sodium bicarbonate, and absorbance values were determined
at 420 nm. Human embryonic kidney Flp-In 293 cells and 293 cells were
included in each assay set as positive and negative controls, respectively.
Stable clones with a single plasmid integrated into the correct, unique
chromosomal site were those that demonstrated and maintained no detectable β-galactosidase expression, poor or no growth in DMEM containing 100 μg/ml Zeocin, normal cell morphology, and good HARE protein
expression. Suitable clones were maintained in DMEM containing 100 μg/
ml hygromycin B and 8% fetal bovine serum.
Western and Ligand Blot Assays—Western blotting was performed as
described by Burnette (22) with minor modifications. Cell lysates were
mixed with equal volumes of 2× SDS sample buffer (21), without reducing agent, to give final concentrations of 16 mm Tris-HCl, pH 6.8, 2%
(w/v) SDS, 5% glycerol (v/v), and 0.01% bromphenol blue. After SDSPAGE, the contents of the gel were electrotransferred to a nitrocellulose membrane overnight at 10 V at 4 °C using 25 mm Tris, pH 8.3, 192
mm glycine, 20% methanol, and 0.01% SDS in a Genie blotter apparatus
(Idea Scientific). For the ligand blot assay, the nitrocellulose membrane
was treated first with TBS containing 0.1% Tween 20 at 4 °C for 2 h, or
TBST overnight, and then incubated with 1–2 μg/ml 125I-HA in 150 mm
NaCl, 10 mm HEPES, pH 7.4, and 5 mm EDTA without, or with, a 100to 150-fold excess of nonlabeled HA (as competitor) to assess total and
nonspecific binding, respectively (23). The nitrocellulose membrane was
washed with TBST five times for 5 min each and dried at room temperature. Bound 125I-HA was detected by autoradiography using Kodak BioMax MS or MR film exposed at –85 °C for 6–48 h. Nonspecific binding in
this assay is typically <5%.
For Western analysis, the nitrocellulose membranes were blocked
with 1% BSA in TBS at 4 °C overnight either after the ligand blot assay
(the membranes were rewet with TBST first) or directly after SDS-PAGE
and electrotransfer. The membrane was then incubated with anti-rat
HARE mAbs (e.g. 1 μg/ml IgG) at 22 °C for 1 h, washed three times for
5 min each with TBST, and incubated with goat anti-mouse Ig-alkaline
phosphatase conjugate (1:1500 dilution) for 1 h at room temperature. The
nitrocellulose was washed with TBST five times for 5 min each and incubated with p-nitro blue tetrazolium and sodium 5-bromo-4-chloro-3-indolyl phosphate p-toluidine for color development (Bio-Rad), which was
stopped by washing the membrane with distilled water.
125I-HA Binding or Endocytosis Assays—Stably transfected 190-kDa
hHARE cell lines were grown to confluence in DMEM containing 8% fetal calf serum and 100 μg/ml hygromycin B in tissue culture multiwell
dishes (usually 24-well plates). The cells were washed with HBSS and incubated at 37 °C in fresh medium without serum for 30–60 min, the plates
were then placed on ice, and the cells washed once or twice with HBSS
prior to the experiment. Medium containing 1–2 μg/ml 125I-HA with or
without the noted concentration of IgG or other GAG (as competitor) was
added to each well, and the cells were incubated either on ice for 60 min
to assess cell surface binding or at 37 °C to allow internalization of ligand.
To assess HA binding by the total cell receptor population, 0.055% (w/v)
digitonin was added to the medium to permeabilize the cells (24, 25). At
the noted times, the medium was removed by aspiration, the cells were
washed three times with HBSS and lysed in 0.3 n NaOH, and radioactivity and protein content were determined. Values were normalized for cell
protein content per well and are presented as cpm/μg of protein. In some
cases, HA data are expressed as cpm or femtomoles per million cells. For
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Flp-In 293 cells, the mean protein content was determined to be 398 ± 85
μg of protein/106 cells (n = 6).
125I-HA Degradation Assay—Degradation of 125I-HA was measured by
a cetylpyridinium chloride precipitation assay as described by McGary et
al. (26). 50-μl samples of medium were mixed with 250 μl of 1 mg/ml HA
in 1.5-ml microcentrifuge tubes. Alternatively, 100-μl samples of cell lysate
(in 0.3 n NaOH) were mixed with 47 μl of 0.6 n HCl, 28 μl of distilled water, and 125 μl of 2.0 mg/ml HA. After mixing at room temperature, 300
μl of 6% (w/v) cetylpyridinium chloride in distilled water was added, and
the tubes were mixed by vortexing. After 10 min, the samples were centrifuged at 22 °C for 5 min at 9000 rpm in an Eppendorf model 5417 microcentrifuge, using a swinging bucket rotor. A sample (300 μl) of the supernatant was taken for determination of radioactivity, and the remainder
was removed by aspiration. The tip of the tube containing the precipitated
pellet was cut off then put in a gamma counter tube, and radioactivity was
determined. Degradation was measured as the time-dependent increase
of nonprecipitable radioactivity. At least 80% of the total radioactivity was
precipitable at the beginning of each experiment.
General—Protein content was determined by the method of Bradford (27) using BSA as a standard. SDS-PAGE was performed according
to the method of Laemmli (21). 125I radioactivity was measured using a
Packard Auto-Gamma Counting system. Digital images were captured
using an Alpha Innotech Fluorochem 8000. Images were taken into Corel
Photo Paint (version 9.0) as JPG files, cropped and processed identically,
and then transferred to Corel Draw (version 9.0) for annotation. N-terminal amino acid sequence analysis was performed by the University of
Oklahoma Health Sciences Center, Molecular Biology Resource Facility.

Results
Expression of Recombinant Human 190-kDa HARE—We recently purified two hHARE proteins, of 190 and 315 kDa, from
spleen extracts and then molecularly cloned a partial cDNA
from pooled human lymph node and spleen that encoded part
or all of the subunits in these two isoforms (10). The 190-kDa
hHARE protein is not expressed from a unique mRNA, but
rather is encoded by a 4383-bp region (1461 amino acids) at the
3′ end of the full-length Stab 2 coding region. To express the
190-kDa protein, we created an artificial cDNA for a recombinant 190-kDa hHARE in the pSecTag/FRT/V5/His-TOPO
expression vector. For proper membrane orientation and trafficking to the cell surface, the pSecTag vector provides an immunoglobulin κ-chain secretion signal sequence fused at the N
terminus of the protein. Transiently transfected Flp-In 293 cells
expressed sufficiently high levels of the recombinant 190-kDa
hHARE to mediate the specific binding and internalization of
125I-HA (Figure 1). Compared with vector alone, cells transfected with hHARE cDNA internalized ~4 times the amount
of HA, and this uptake was completely blocked by unlabeled
HA. Specific HA uptake, therefore, was ~80% of the total.
The potential advantage of using Flp-In 293 cells as the parental cell line for generation of stable cell lines expressing
hHARE is that all clones should be virtually identical if the plasmid inserts at only the single unique chromosome site containing the engineered integration site. Correct integration at this
site interrupts a β-galactosidase gene and a Zeocin resistance
gene in the engineered site. Clones containing a single plasmid
insertion at the correct engineered site are, therefore, hygromycin B-resistant, negative for β-galactosidase activity, and Zeocin-sensitive. If plasmid insertion occurs at other chromosome
sites, rather than the correct engineered site, then clones will express β-galactosidase and be Zeocin-resistant. Out of 41 stably
transfected clones that we selected and characterized, three (#9,
#14, and #40) had no detectable β-galactosidase activity, were
Zeocin-sensitive, and were judged to contain a plasmid insertion at the unique engineered site.
A protein of the correct size for the 190-kDa hHARE was
expressed in the three selected stable Flp-In 293 cell lines, and
this protein bound 125I-HA with >98% specificity in a ligand
blot assay following SDS-PAGE and electrotransfer (Figure
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Figure 1. Transiently transfected 293 Flp-In cells express the HA-binding recombinant 190-kDa hHARE protein. 293 Flp-In cells (5 × 104 per
well) grown in 24-well plates were transfected with pSecTag-190-kDa
hHARE/ExGEN500 or pSecTag/ExGEN500 complexes and allowed
to recover for 2 days. The transfected cells were allowed to bind and
endocytose 1 μg/ml 125I-HA with (H+C) or without (H) 100 μg/ml unlabeled HA in serum-free medium for 3 h at 37 °C. Cells were washed
with ice-cold HBSS and solubilized in 0.3 m NaOH, and radioactivity
and protein were determined (n = 3; ±S.E.).

2A). The 190-kDa hHARE protein expressed in Flp-In 293 cells
had the characteristics previously found for native hHARE
purified from spleen (10), and expression of the 190-kDa
hHARE did not alter the morphology of Flp-In 293 cells. The
recombinant nonreduced protein was recognized in Western
blots by the three anti-rHARE mAbs that cross-reacted with
native hHARE (mAbs 30, 154, and 159) but not mAbs 28, 174,
235, and 467 (Figure 2B, NR). Similarly, the reduced 190-kDa
hHARE protein reacted with only mAbs 159 and 174 (Figure
2B, R). Based on its HA-binding activity in these in vivo and
in vitro assays, the recombinant hHARE protein appeared to
be folded properly. Consistent with this interpretation, three
other characteristics of the recombinant hHARE were identical to those of the native protein (10). Reduction of disulfide
bonds resulted in slower migration of the 190-kDa hHARE in
SDS-PAGE compared with the nonreduced protein (Figure 2C,
lanes 1 and 3, WB). Reduction of disulfide bonds also caused
loss of HA-binding activity (Figure 2C, lanes 1 and 3, AR). After treatment with endoglycosidase-F to release N-linked oligosaccharides, the recombinant protein migrated at a position
corresponding to a loss of ~25 kDa (Figure 2C, lanes 3 and 4,
WB). The de-N-glycosylated hHARE protein was still able to
bind HA in this ligand blot format (Figure 2C, lane 4, AR). In
addition, anti-V5 antibody recognition of the C-terminal epitope provided by the vector was suitable for immunoprecipitation (not shown).
HA Binding and Internalization by Cells Expressing the 190kDa hHARE—The specific binding of 125I-HA at 4 °C by stable cell lines was typical for a membrane-bound receptor;
binding kinetics was hyperbolic and saturated after about 90
min (Figure 3). Essentially no specific binding of 125I-HA occurred in the control cells transfected with empty vector, consistent with the absence of any significant HA receptor activity
in 293 cells (Table I). Also, as found for other endocytic, recycling receptors (e.g. the asialoglycoprotein and mannose receptors), about 30–50% of the total cellular hHARE population
was on the cell surface, and the remainder was intracellular.
The native rHARE in isolated LECs is an active endocytic receptor that recycles so that HA can be continually internalized and delivered to lysosomes for degradation over a period
of many hours to days (7, 17, 26). To assess the ability of the
recombinant 190-kDa hHARE to recycle, cells were allowed
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Figure 3. Kinetics of 125I-HA binding by stable cell lines expressing the
190-kDa hHARE. Confluent cell cultures of hHARE expression clones
#9 (•) and #14 (▪) were incubated at 37 °C in medium without serum
for 60 min. The plates were placed on ice, and the wells were washed
once with HBSS. The cells were permeabilized at 4 °C with 0.55% digitonin in PBS to allow access to both surface and internal receptors (24,
25). The cells were washed and then incubated in medium containing
1.5 μg/ml 125I-HA with or without 150 μg/ml unlabeled HA. At the
noted times, the cells were washed three times with HBSS and solubilized in 0.3 n NaOH, and protein and radioactivity were determined
as under “Experimental Procedures.” Data shown represent specific
binding; each point is the average of duplicate wells without excess
HA (total binding) minus the average of duplicate wells with excess
HA (nonspecific binding).

Figure 2. The 190-kDa hHARE is expressed abundantly and is biologically functional in stably transfected 293 Flp-In cells. A, whole cell lysates from three clones expressing the 190-kDa hHARE (9, 14, and
40) and one clone transfected with empty vector (EV) were subjected
to nonreducing SDS-PAGE using a 5% gel, followed by electrotransfer to nitrocellulose. Bottom panels: after blocking in 0.1% Tween-20 in
TBS for 3 h at room temperature, ligand blotting and autoradiography (AR) were performed, using 1.0 μg/ml 125I-HA with (left) or without (right) 100 μg/ml unlabeled HA, as described under “Experimental
Procedures.” Top panels: the same nitrocellulose strips were then rewetted and blocked with 1% BSA in TBS, and Western blot (WB) analysis
was performed using a mixture of mAb-30, mAb-154, and mAb-159. B,
whole cell lysates from clone #9 were subjected to nonreducing (NR) or
reducing (R) SDS-PAGE using a 5% gel and electrotransfer to nitrocellulose. After blocking for 2 h in 1% BSA in TBS, the nitrocellulose was cut
into strips and subjected to Western blot analysis with 1 μg/ml of the
indicated seven mAbs previously raised against the rat 175-kDa HARE.
C, cells expressing the 190-kDa hHARE protein were lysed in Laemmli
buffer and either treated with endoglycosidase F and/or reduced with
10 mm dithiothreitol. Proteins were separated on a 5% SDS-PAGE. Bottom panel: the transfer was incubated with 1 μg/ml 125I-HA with (left) or
without (right) 100 μg/ml unlabeled HA for 2 h at 4 °C and washed, and
autoradiography was performed. Top panel: the nitrocellulose was then
rewetted in 1% BSA in TBS, and Western blot analysis was performed to
identify hHARE using anti-V5 antibody.

to internalize 125I-HA for 4 h, and the amount of specific HA
uptake was calculated as the number of cell surface receptor
equivalents. This estimates the approximate number of times
that a cohort of cell surface HARE proteins would have to be
used to achieve the observed level of HA uptake. For 190-kDa
hHARE Flp-In 293 clones 9 and 14, these recycling ratios were
25 and 32, respectively (Table I). Based on these values of 25–

32 surface equivalents of HA internalized in 240 min, the estimated individual receptor recycling time is 7.5–9.6 min, which
is identical to the recycling times reported for all the known
coated-pit-mediated clearance receptors that recycle (7, 19).
Consistent with the conclusion that the recombinant 190kDa hHARE is a recycling receptor able to mediate the continuous endocytosis of ligand, the Flp-In 293 cell lines expressing
hHARE, but not the vector-alone control, were able to internalize 125I-HA for ≥20 h before cellular accumulation appeared
to level off (Figure 4). The apparent saturation of HA uptake
is a steady-state situation, however, because cells are still endocytosing 125I-HA while they are releasing radioactive degradation products into the medium at the same rate. The ability
of cells to process (i.e. internalize, degrade, and secrete degradation products) large amounts of ligand over many hours or
days is characteristic of recycling receptors that operate via the
coatedpit pathway (7, 19, 28).
Scatchard Analysis of 125I-HA Binding by Recombinant 190-kDa
hHARE—Because no ligand binding information exists for the
individual hHARE species, equilibrium binding studies were
performed using 190hHARE Flp-In 293 clones #9 and #14 to
determine total receptor content and the affinity of the HAhHARE interaction (Figure 5). Based on the concentration of unlabeled HA required for half-maximal competition of 125I-HA
binding, the apparent Km for HA binding is 1–2 μg/ml or ~10
nm (Figure 5A). When these data were normalized for the specific radioactivity of the bound 125I-HA at each point, the resulting binding isotherm was hyperbolic, which is typical of many
receptor-ligand interactions, and binding approached saturation at >80 μm HA (Figure 5B). When analyzed according to
the method of Scatchard (29), the data in replicate experiments
were best fit by a single straight line (cc ≥ 0.9), indicating that a
single class of noninteracting HA binding sites was present in
digitonin-permeabilized cells (Figure 5C). Based on two independent experiments with both clones #9 and #14 (n = 8) the
mean (±S.D.) Bmax and Kd values were 196 ± 45 fmol of total HA
binding sites/106 cells and 7.2 ± 1.2 nm, respectively. The Bmax
value corresponds to ~118,000 total HA binding sites per cell.
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Figure 4. The recombinant 190-kDa hHARE mediates continuous endocytosis and degradation of 125I-HA. A, confluent cell cultures of
190hHARE-expressing clones #9 (●) and #14 (■) and empty vector
control clone #13 (▼), in 24-well tissue culture plates, were incubated
at 37 °C in medium without serum for 30 min. The plates were then
placed on ice, and the cells were washed once with HBSS. Medium
containing 1.6 μg/ml 125I-HA with or without 160 μg/ml unlabeled
HA was added to each well, and the cells were incubated at 37 °Cfor
up to 4 h to allow internalization. At the noted times, the medium was
removed, and the cells were washed three times with 1 ml of HBSS
and lysed in 0.3 n NaOH, and cell protein content and cell-associated
radioactivity were determined. The data are shown as specific uptake;
the average radioactivity values of duplicates for total uptake minus
the average of duplicates for nonspecific uptake. B, clone #14, expressing the 190-kDa hHARE, was cultured in 4-well tissue culture plates,
and processed as in A. In addition, degraded 125I-HA that was cell-associated and in the medium were also measured at the noted times, as
described under “Experimental Procedures.” The plots show radioactivity (representing intact and degraded HA) associated with the cells
(■) and the total degraded 125I-HA (●), i.e. products still inside the cell
plus those in the medium.

GAG Specificity of the Recombinant 190-kDa hHARE—The
GAG specificities of the two hHARE isoforms have not been
determined. Using the stable 190hHARE Flp-In 293 cell lines,
we examined the ability of individual purified GAG chains to
block the endocytosis of 125I-HA. Even at 100 μg/ml, KS, HS,
and heparin did not compete for HA binding and uptake at
37 °C, and DS showed a modest ~15% inhibition (Figure 6).
This latter slight inhibition by DS appears to be significant,
because it was observed in other experiments as noted be-
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low. CS-A was the most effective inhibitor, although its blocking ability was not comparable to that of HA, e.g. at 30 μg/
ml ~45% inhibition was observed with CS-A versus ~70% inhibition with HA (Figure 6A). Four other GAGs, including
chondroitin (Figure 6A) and CS-C, CS-D, and CS-E (Figure 6B)
gave very similar titration profiles, with ~50% inhibition at 100
μg/ml. For comparison, 100 μg/ml HA blocked 125I-HA uptake by ~87%. In contrast to these results at 37 °C, none of the
GAGs tested, except for HA, competed for 125I-HA binding to
190hHARE Flp-In 293 cells at 4 °C (Figure 7). 125I-HA binding
in the presence of the other nine GAGs ranged within 10% of
the no-addition control value. The binding of GAGs other than
HA to the 190-kDa hHARE protein, thus, appears to be very
temperature-dependent.
The ability of the 190-kDa hHARE to interact with GAGs
was also assessed in a ligand blot format in which whole cell
extracts were probed, in a Western blot format, with 125I-HA
(23). As shown in Figure 1A, the level of hHARE protein expression in extracts is high enough to obtain an excellent signal, by autoradiography, in this assay within 6–18 h. The ability of various GAGs to compete for 125I-HA binding to the
190-kDa hHARE in the ligand blot assay (Figure 8) closely paralleled the pattern seen for competition of endocytosis by cells,
with the exception of HS. No competition was observed with
KS or Hep. As with live cells, Chon, DS, and all the CS types
showed significant competition. In contrast, 100 μg/ml HS
showed no effect on HA endocytosis in live cells (Figure 6B),
whereas 50 μg/ml HS inhibited 125I-HA binding by 40% in the
in vitro ligand blot assay.
It should be informative to compare the GAG specificities of the rat and human small HARE isoforms, because the
amino acid sequences of the extracellular domains of these
two proteins are 80% identical (10). Such GAG specificity differences might reflect significant differences between species
in the biology of HARE or its role in GAG turnover. Figure 9
compares the abilities of various GAGs to compete for 125I-HA
endocytosis by isolated rat LECs expressing both rat HARE
isoforms, SK-HARE cells expressing the 175-kDa rHARE, and
Flp-In 293 cells expressing the 190-kDa hHARE. In each of the
three cell types, little or no competition was observed with KS,
HS, or Hep. DS competed for HA uptake to the same slight
extent (~25–30%) in cells expressing either hHARE or rHARE.
The four CS variants competed for HA uptake by both HARE
proteins, although the patterns were not identical. The effects
of CS-A and CS-D were essentially the same, whereas the preference for CS-C or CS-E was switched between the rat and human HARE proteins. HA-binding to the hHARE was competed better by CS-E, whereas binding to the rHARE was
competed better by CS-C. The greatest difference between the
rat and human HARE was observed for competition by Chon.
The hHARE appeared to interact more strongly with Chon
(50% inhibition) than did the rHARE (~10% inhibition).

Table I. Surface and intracellular HA binding and receptor recycling during endocytosis. Stable Flp-In 293 cell lines transfected with empty vector (clone #EV13) or the 190 hHARE cDNA (clones #9 and #14) were grown to confluence, chilled on ice, washed with HBSS, and incubated with
medium containing 1.5 μg/ml 125I-HA with or without digitonin as described under “Experimental Procedures” to assess total or cell surface
binding, respectively. A set of parallel cell cultures was incubated at 37 °C for 4 h in medium containing 1.5 μg/ml 125I-HA. Nonspecific binding or
endocytosis was assessed in the presence of a 100-fold excess of unlabeled HA. Specific values shown are the mean ± S.E. (n = 10 for clones #9 and
#14) or the average of duplicates for clone #EV13. The receptor recycling ratio is the amount of specific HA endocytosis divided by the specific cell
surface HA binding. Regardless of cell type, when vertebrate cells are treated with digitonin under the conditions used here, ~50% of the total cellular protein is lost, representing the cytoplasmic contents (24). Therefore, the protein yield for permeable cells is about half that for intact cells.
							
HARE
Clone #
Surface
Specificity
Total
Specificity
Endocytosis
Specificity
recycling
9
14
EV13

cpm/μg
%
12.4 ± 1.9
63.3 ± 10.0
11.9 ± 3.0
50.7 ± 17.3
1.3 		

cpm/μg
%
54.2 ± 15.8
75.2 ± 9.5
62.7 ± 21.7
71.3 ± 10.8
12.3 		

cpm/_g
%
300.8 ± 34.8
90.1 ± 2.0
365.4 ± 26.8
90.0 ± 2.1
1.6 		

Endo/surface
24.8 ± 4.2
32.3 ± 8.1
1.3
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and characterization (8–10, 14). Seven of these mAbs recognize both nonreduced rHARE proteins and were useful for a
variety of immunoprocedures. In particular, mAb-174 was extremely useful, because it completely blocks HA binding to
the rHARE in LECs (30), in SK-HARE cells (9), or in the ligand
blot assay (8). A second mAb, #235, partially inhibited HA
binding to rHARE to a level of ~50%, indicating that HA binding likely involves multiple protein regions (epitopes). We recently used mAb-174 to demonstrate that HARE is responsible
for the ability of liver to remove circulating HA, because this
mAb blocked essentially all 125I-HA uptake in a perfused liver
system (30). Although mAb-174 and mAb-235 did not recognize hHARE, three of the seven anti-HARE mAbs (#30, #154,
and #159) cross-reacted with both native hHARE isoforms (10)
and with the recombinant 190-kDa hHARE (Figure 2B). Nonetheless, we tested whether any of the anti-HARE mAbs could
inhibit the endocytosis of 125I-HA by 190hHARE Flp-In 293
cell lines (Figure 10). Surprisingly, although mAb-159 had no
effect on HA uptake (even at 30 μg/ml), partial inhibition of
specific HA endocytosis was observed with both mAb-30 and
mAb-154 (Figure 10A). Negative controls for these effects included the other four anti-HARE mAbs (#28, #174, #235, and
#467), as well as IgG and mouse serum (not shown), any of
which caused ≤8% inhibition at concentrations up to 30 μg/
ml. Experiments to assess the effects of various mAb combinations on HA uptake at 37 °C showed that the inhibitory mAbs
(#30 and #154) were not additive (Figure 10B). The maximum
partial inhibition of specific HA endocytosis by mAb-30 or
mAb-154 was, respectively, ~20–30% and 50–60%.
Discussion

Figure 5. Kinetic and Scatchard analyses of 125I-HA binding to FlpIn 293 cells expressing recombinant 190-kDa hHARE. 190hHARE cell
lines #9 (■) and #14 (●) were cultured in 4- or 6-well plates until confluent. The cells were incubated for 60 min at 37 °C in medium without serum and then chilled to 4 °C for all subsequent steps. The cells
were washed with HBSS, permeabilized with 0.055% digitonin for 15
min, and then washed with HBSS. At the end of each experiment, cells
were washed with HBSS and cell-associated radioactivity and cell protein were determined as described under “Experimental Procedures.”
A, after washing the cells, medium containing 0.1 μg/ml 125I-HA with
the indicated amount of unlabeled HA was added to each well, and
the cells were allowed to bind the HA on ice for 90 min. Specific binding was ~90%, as assessed in the presence of the highest HA concentration. B, the data in A for clones #9 and #14 were recalculated as specific HA binding (femtomoles of HA/106 cells). The data are the mean
± S.D. of duplicates for each of the two clones (n = 4). C, after the cells
were allowed to bind HA on ice for 90 min as in A, the medium was
removed to determine free 125I-HA, and the cells were washed and
cell-associated 125I-HA was determined. The specifically bound HA
was calculated for the experiment shown in B, and the results are presented in the format of Scatchard (29) as the average of duplicates for
each cell line.

Inhibition of 125I-HA Endocytosis by Anti-HARE mAbs—We
previously developed a panel of eight mouse mAbs against
the rat 175-kDa HARE protein to facilitate HARE purification

HA and CS turn over continuously in ECMs throughout the
body. For humans, the HA turnover rate is so fast (e.g. ~24 h in
skin) that about one-third of total body HA is degraded and resynthesized daily (6). Partially digested native HA molecules
are released from tissue matrices as large HA fragments of ~106
Da that would still contain bound aggregating proteoglycans
(e.g. aggrecan or brevican) and Link proteins (31–33). The released ECM fragments would also contain covalently attached
CS and other GAG chains, as well as a variety of bound ECM
proteins and growth factors. Thus, multiple components associated with these HA-proteoglycan fragments are simultaneously released from an ECM and then enter lymphatic vessels
and flow to regional lymph nodes. Lymph nodes are the initial
and primary sites for the clearance of the HA and CS, accounting for ~85% of the HA degradation. Liver is the second clearance site, after the lymph node effluent enters the circulation,
accounting for ~15% of the total body HA, and presumably CS,
turnover. The clearance and degradation of HA and CS in liver
and lymph nodes is mediated by HARE, which is expressed in
the sinusoidal endothelial cells of these tissues (8–13).
Although no studies have yet addressed its role in normal
health and in various diseases or pathologies, HARE is likely
to be important in human physiology. Despite the high turnover rate of HA, the normal steady-state concentration of HA
in blood (i.e. 10–100 ng/ml) is very low (2, 6). The HA/CS
clearance systems utilizing HARE in lymph node and liver,
therefore, function very efficiently, indicating that the removal
of HA from lymph fluid and blood is important for normal
health. First, one would predict that, if HA levels increased,
particularly if the HA mass was large, then the increased viscosity of blood might create potentially adverse situations, e.g.
erythrocyte passage in narrow microcapillaries could be impaired. Second, because HA binds to human fibrinogen (34)
and stimulates fibrin clot formation in vitro (35), elevated HA
levels could alter normal coagulation homeostasis. Finally,
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Figure 6. Only some non-HA GAGs compete for 125I-HA endocytosis at 37 °C by stable cell lines expressing the recombinant 190-kDa hHARE. Cells
from 190-kDa hHARE Flp-In 293 clones #9 and #14 were incubated at 37 °C for 3 h in medium containing 1.5 μg/ml 125I-HA with 3 to 100 μg/ml of
the indicated GAG. The values for competition of 125I-HA internalization by unlabeled GAGs or HA (expressed as a percentage of the no-competitor control) are the average of duplicates from the two clones (n = 4). A, keratan sulfate (▲), dermatan sulfate (♦), chondroitin (■), chondroitin sulfate A (▼), HA (●). B, heparan sulfate (◊), heparin (), chondroitin sulfate E (∆), chondroitin sulfate D (○), chondroitin C (□), and HA (●).

Figure 7. Chondroitin sulfates and other GAGs do not compete well
for 125I-HA binding at 4 °C by Flp-In 293 cells expressing the 190-kDa
hHARE. After a serum-free incubation and wash with HBSS, cells
from 190-kDa hHARE clones #9 and #14 were incubated at 4 °C for 2
h in medium containing 1.5 μg/ml 125I-HA and 50 μg/ml of the indicated GAG. The values for each GAG are the mean of duplicate samples from both clones (n = 4) ± S.E.

Figure 8. Other GAGs compete for 125I-HA binding to recombinant 190-kDa hHARE in a ligand blot assay. Extracts prepared from
190hHARE clone #14 cells were subjected to SDS-PAGE and electroblotted as described under “Experimental Procedures.” The nitrocellulose was blocked with TBS and 0.1% Tween 20 at room temperature for 3 h, and 3-mm strips were cut and placed in Buffer 1 with
0.5% sodium azide, 5 mm EDTA, 0.05 μg/ml 125I-HA, and 50 μg/ml
of the indicated GAG or HA. The strips were incubated at 4 °C for
2 h on a rocking platform. The medium was then removed, and the
strips were washed extensively with TBST for 20 min, allowed to air
dry, and attached to filter paper for autoradiography with BioMax MS
film. The exposure shown was for 19.5 h at –85 °C with two intensifying screens. The graph shows the average densitometry values ± S.E.
from three separate samples for each GAG.

several diseases, including some cancers (36), psoriasis (37),
scleroderma (38), rheumatoid arthritis (39), and liver cirrhosis
(40, 41), are associated with elevated levels of HA in serum.
Over the last decade, numerous studies have suggested that
the HA clearance function of liver can be used as a diagnostic
tool to detect and monitor liver failure (42). This hepatic function of LECs may also be a prognostic indicator of success in
liver transplant patients.
In this study, we created an artificial cDNA to express a recombinant form of the small spleen hHARE isoform in stable
cell lines. This enabled us to characterize for the first time the
GAG specificity and endocytic activity of the small hHARE
isoform in the absence of the larger hHARE isoform. Several
key characteristics of the 190-kDa hHARE are very similar to
those of the 175-kDa rHARE. Both smaller HARE isoforms are
functional endocytic HA receptors with the appropriate, as

yet unidentified, sorting signals for targeting HARE to coated
pits and then through an intracellular receptor recycling itinerary. Each HARE, although expressed in different cell types,
mediated the continuous endocytosis of HA and its delivery
to lysosomes for degradation. The rate of hHARE recycling
in Flp-In 293 cell lines (i.e. one cell surface equivalent per 7–9
min) was comparable to that determined in primary rat LECs
(17). The apparently slower rate of rHARE recycling in SKHep-1 cell lines (~20 min) is likely due to a decreased capacity of the coated pit pathway in this latter cell line (9, 43, 44),
rather than to intrinsic differences between the recombinant
rHARE and hHARE. The affinities of the smaller rHARE and
hHARE were also very similar, with Kd values of 4.1 and 7.2
nm, respectively.
Two significant differences, which might be related, between the rat and human HARE proteins are their slightly
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Figure 9. The human and rat small HARE isoforms show different
GAG specificities for competition of 125I-HA endocytosis. Flp-In 293
190hHARE clones #9 and #14 (white bars), SK-HARE clones #26 and
#35 (expressing recombinant the rat 175-kDa HARE), and liver sinusoidal endothelial cells (from freshly perfused rat liver) were incubated at 37 °C for 3 h with medium containing either 1 μg/ml 125IHA and 30 μg/ml of the indicated GAG (for SK-HARE and liver
cells) or 1.5 μg/ml 125I-HA and 100 μg/ml of the indicated GAG (for
190hHARE 293 cells). Cells were then washed and lysed, and the radioactivity and protein content were determined as described under “Experimental Procedures.” Each GAG value is the mean ± S.E.
of at least four individual wells (e.g. two wells for each of two clones
or LEC preparations) and is calculated as a percentage of the 125I-HA
control (without competitor).

different GAG specificities and their very different profiles
for anti-HARE mAb inhibition of HA binding. The 190-kDa
hHARE has a broad specificity for sulfated and nonsulfated
GAGs, yet this recognition is not indiscriminant, because HA
binding is not affected by KS, HS, or Hep. Thus, the 190-kDa
hHARE recognizes HA and chondroitin, the two least negatively charged GAGs, as well as three CS variants with different levels and patterns of sulfation. The two GAGs with the
greatest negative charge, HS and Hep, are not recognized. In
contrast, all the CS variants tested were able to compete for
HA binding. Although the pattern of inhibition by CS variants
was similar to that for the 175-kDa rHARE, it was not identical. In particular, the two HARE species differ quantitatively
in their recognition of CS-C and CS-E.
The GlcUA-GlcNAc disaccharide units in HA and the GlcUA-GalNAc disaccharide units of chondroitin were recognized by the 190-kDa hHARE. HARE also recognized all of
the sulfated CS types tested, despite differences in the position and number of sulfates among their disaccharide units.
Chondroitins sulfated at GalNAc positions C4, C6, or C4,6 (i.e.
CS-A, CS-C, and CS-E) or at C6 of GalNAc and C2 of GlcUA
(i.e. CS-D) were effective competitors of HA binding, although
none were as effective as HA. CS-A was a slightly better competitor than the other CS types, all of which were essentially
identical. DS (also called CS-B) was the weakest competitor.
KS contains Gal rather than a uronic acid and was not a competitor. Although Hep and HS are very highly sulfated GAGs,
they were not able to compete for HA binding to the 190-kDa
hHARE. Perhaps HARE can recognize N-acetyl groups in the
amino sugars of some GAGs, but not the N-sulfated glucosamine residues characteristic of Hep and HS.
The greatest difference in GAG specificity between the rat
and human proteins was with Chon, which poorly competes
for HA binding by the rHARE. The 190-kDa hHARE protein
appears to recognize Chon almost as well as most of the CS

Figure 10. Inhibition by anti-HARE mAbs of 125I-HA uptake by cells
expressing recombinant 190-kDa hHARE. Flp-In 293 190hHARE
clones #9 and #14 were cultured and processed as described in Figure 4. A, the cells were allowed to bind and endocytose 1.5 μg/ml of
125I-HA for 3 h at 37 °C with no additions, or the noted concentration
of anti-rat HARE mAbs 28 (●), 30 (■), 154(▲), 159 (▼), 174 (♦), 235
(○), and 467 (□). The cells were processed as described under “Experimental Procedures.” The values shown are the average of two replicate wells from each clone (n = 4), expressed as a percentage of the noaddition control specific binding values. Mouse IgG (not shown) at 10
μg/ml was 103 ± 5% of the control value. Specific binding (CPM/μg
of cell protein), as assessed in the presence of a 100-fold excess of unlabeled HA, was 87%. B, the indicated purified antibodies were used
singly or in combination, at concentrations of 20 μg/ml, in an experiment performed as described in A. Nonspecific endocytosis was assessed in the presence of 75 μg/ml unlabeled HA.

types. These slight differences between species in relative preference for various GAGs may be reflected in the more dramatic differences in the inhibition of their HA binding ability by mAbs. HA binding and endocytosis by the small (or
large) rat HARE proteins is completely blocked by mAb-174
and partially blocked by mAb-235, whereas no inhibition of ligand binding or uptake was observed with the other five antiHARE mAbs that recognize these proteins in Western blots
and various immunoprocedures. In contrast, we found here
that mAb-30 and mAb-154 partially inhibit HA binding and
endocytosis by the 190-kDa hHARE. The other anti-HARE
mAbs, including mAb-174 and mAb-235, were not inhibitory.
Thus, although mAb-30 and mAb-154 bind to both rHARE
and hHARE, this binding only inhibits HA recognition by the
latter protein.
Another distinctive and unusual feature of the 190-kDa
hHARE was that GAG inhibition of its binding to HA was
temperature-sensitive. Although multiple GAGs were able
to block the binding and endocytosis of 125I-HA mediated by
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hHARE at 37 °C, none of these GAGs could compete for 125IHA binding at 4 °C. Presumably, the extracellular domain of
the 190-kDa hHARE undergoes a substantial conformational
change between 37 °C and 4 °C that virtually eliminates the
binding of GAGs other than HA. However, because our binding studies were indirect and only monitored the binding of
125I-HA, it is possible that a conformational change could also
create a situation wherein both GAGs might bind to separate
sites without interference. Distinguishing between these possibilities must await further direct binding studies between the
various GAGs and the purified 190-kDa hHARE or its extracellular domain.
Taken together the above results indicate that amino acid
sequence differences between the small rat and human HARE
proteins may alter their GAG specificity slightly. These sequence differences may also alter conformations that occur
when mAbs bind to the proteins, so that GAG binding is affected indirectly, and in a species dependent way, by formation of a mAb·HARE complex. It is likely that mAb-30 and
mAb-154 recognize epitopes that are not directly involved in
HA binding by hHARE but that steric factors limit interactions
of the protein with HA. The finding that inhibition with either
mAb is only partial indicates that hHARE likely contains multiple HA binding regions. It also indicates that each hHARE
protein may bind more than one HA molecule. Again, these
or other possible explanations will require epitope mapping
studies and studies to define the GAG binding regions within
the extracellular domain of HARE.
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